|May 26, 2017|
|May 26, 2017|
Currency in KRW
|Full time employees:||--|
Hanmi Science Co., Ltd. is a holding company that engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong, South Korea.
Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. In recent years, the South Korean group has been actively developing new drugs. It has also accelerated overseas expansion, including by setting up a unit in Beijing.
The company's market capitalization puts it in the top tier of South Korean drug companies, alongside Celltrion.
The group was established in 1973 as Hanmi Pharmaceutical. It strengthened its presence in the drug development game in the 2000s. About 20% of sales are reinvested in research and development.
Hanmi has been focusing on clinical trials for diabetes treatments. It expects the diabetes drug market to grow at an average annual pace of over 6% from 2014 to 2023, nearly doubling in size to $42 billion.
The company's operations include original design manufacturing services for major international drugmakers, including France's Sanofi. For this, Hanmi uses a plant in Hwaseong, Gyeonggi Province. It also runs a facility for antibiotics and biotechnology in Pyeongtaek, in the same province.
Hanmi Fine Chemical, another group company, produces active pharmaceutical ingredients for major drugmakers.
In July 2015, Hanmi announced a partnership with German drugmaker Boehringer Ingelheim. The duo aims to develop a pharmaceutical candidate, HM61713, into a new molecularly targeted drug for lung cancer treatment. Hanmi is to put the drug through clinical trials in South Korea, China and Hong Kong, as well as handle sales licensing, production and commercialization in those markets.
Under the deal, Hanmi will start by using $50 million in contract money to conduct clinical development. The South Korean company stands to receive a total of $730 million, based on progress with licensing and other tasks.
In the news
October 19, 2016 9:37 pm JST
October 7, 2016 8:53 pm JST
July 13, 2016 4:51 am JST
April 14, 2016 2:00 am JST
April 13, 2016 7:00 pm JST
South Korea Inc.
February 27, 2016 6:57 am JST
- Local currency
- US Dollar
|Income before tax||5,329.86M|
|Dividends per share||428.15|
|Operating cash flow||85,043.35M|
Currency in KRW
|Income before tax||4.59M|
|Dividends per share||0.36|
|Operating cash flow||73.30M|
Currency in USD
- Co-President, Chief Executive Officer & Director: Jong-Yoon Lim
- Co-President & Director: Sae-Chang Kwon
- Director & Vice President: Jae-Sik Kim
- Co-President & Director: Jong-Soo Woo
- Executive Board Member: Yu-Shik Hwang
- LIM SUNG-GI(34.3%)
- SHIN DONG-GUK(12.1%)
- Hanmi IT(6.4%)
- LIM JONG-YOON(3.5%)
- LIM JU-HYUN(3.5%)
- LIM JONG-HOON(3.1%)
- Hanmi Science Co., Ltd.(2.2%)
- LIM JIN-HEE(1.9%)
- SONG YOUNG-SOOK /HANMI/(1.2%)
- HONG JI-YOON(1.1%)
- Website: http://www.hanmi.co.kr
- Address: 214 Muha-ro, Paltan-myeon, Hwaseong-si, 18536, South Korea
- Phone: +82.31.350.5600
Copyright © 2017 FactSet Research Systems Inc. All rights reserved.